Toshio Shimizu

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Topics

Small Cell Lung Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, Ryoko Seki, Noboru Yamamoto
Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors. Cancer research communications (2024)
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika Paige Hamilton, Toru Mukohara, Aaron E Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitotshi Ichikawa, Shinji Kohsaka, Ryo Sadachi, Akihiro Hirakawa, Akihiko Yoshida, Reiko Makihara Ando, Toshihide Ueno, Mitsuru Yanagaki, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori
Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study. Cancer discovery (2023)
Toshio Shimizu, Jacob M Sands, Kiyotaka Yoh, Alexander I Spira, Edward B Garon, Satoru Kitazono, Melissa Lynne Johnson, Funda Meric-Bernstam, Anthony W Tolcher, Noboru Yamamoto, Jon Greenberg, Yui Kawasaki, Hong Zebger-Gong, Fumiaki Kobayashi, Penny Phillips, Aaron E Lisberg, Rebecca S Heist
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer research communications 3 (7) (2023)
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason John Luke, Sarah M McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa M Kattenhorn, Marc R Pelletier, Shahneen Sandhu
Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia-Ribas, Toshihiko Doi, Noboru Yamamoto
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer research communications 2 (11) (2022)
Shunji Takahashi, Yutaka Fujiwara, Kenji Nakano, Toshio Shimizu, Junichi Tomomatsu, Takafumi Koyama, Mariko Ogura, Masaya Tachibana, Yasuyuki Kakurai, Tomonari Yamashita, Sakura Sakajiri, Noboru Yamamoto
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer science 112 (6) (2021)
Hironobu Minami, Naomi Kiyota, Shiro Kimbara, Yuichi Ando, Tomoya Shimokata, Atsushi Ohtsu, Nozomu Fuse, Yasutoshi Kuboki, Toshio Shimizu, Noboru Yamamoto, Kazuto Nishio, Yutaka Kawakami, Shin-Ichi Nihira, Kazuhiro Sase, Takahiro Nonaka, Hideaki Takahashi, Yukiko Komori, Koshin Kiyohara
Guidelines for clinical evaluation of anti-cancer drugs. Cancer science 112 (7) (2021)
Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V Faller, Lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-Pyo Kim
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Targeted oncology (2021)
Toshio Shimizu, Dong-Wan Kim, Herbert H Loong, Chia-Chi Lin, Matthew Chau Hsien Ng, Noboru Yamamoto, Brigette Ma, Daniel Sw Tan
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. Asia-Pacific journal of clinical oncology 17 (4) (2021)
Toshio Shimizu, Kazuto Nishio, Kazuko Sakai, Isamu Okamoto, Kunio Okamoto, Masayuki Takeda, Maiko Morishita, Kazuhiko Nakagawa
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology 86 (2) (2020)